Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px
Document › Details

Vivoryon Therapeutics AG. (8/29/19). "Press Release: Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update". Halle (Saale).

Organisations Organisation Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
  Group Vivoryon (Group)
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
Products Product QC inhibitor (glutam(in)yl cyclase inhibitor)
  Product 2 PQ912 (Probiodrug)
Index term Index term Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al.
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)
     


   
Record changed: 2019-09-03

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Vivoryon (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px




» top